Cost-Effectiveness of Dapagliflozin Versus DPP-4 Inhibitors as an Add-On to Metformin in the Treatment of Type 2 Diabetes Mellitus From a UK Healthcare System Perspective

BMC Health Services Research - United Kingdom
doi 10.1186/s12913-015-1139-y
Full Text
Abstract

Available in full text

Categories
Health Policy
Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Dapagliflozin: Cost-Effectiveness as an Add-On Therapy to Metformin in the Treatment of Type 2 Diabetes (T2DM) in Argentina and Chile

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Pdb81 - Dapagliflozin Is Cost-Effective Compared to DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus in the Netherlands

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Dapagliflozin (Forxiga®) Versus Glipizide as Add-On Therapies in Type 2 Diabetes Mellitus (T2dm); An Update of the Cost-Effectiveness Based on Long-Term Clinical Evidence From Uk NHS Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Cost-Effectiveness Analysis of Linagliptin Versus Sulfonylurea as Add-On Treatment to Metformin for the Treatment of Diabetes Mellitus Type 2 Patients in Indonesia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-On Therapy to Metformin in Patients With Uncontrolled Type 2 Diabetes Mellitus

Diabetes Therapy
Internal MedicineEndocrinologyMetabolismDiabetes
2016English

Cost-Effectiveness of Dapagliflozin as Add-On to Insulin for the Treatment of Type 2 Diabetes in the Netherlands

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Dipeptidyl Peptidase 4 (Dpp-4) Inhibitors for the Treatment of Type 2 Diabetes Mellitus

Journal of thee Medical Sciences (Berkala Ilmu Kedokteran)
2016English

Prescription of DPP-4 Inhibitors to Type 2 Diabetes Mellitus Patients With Renal Impairment: A UK Primary Care Experience

Clinical Therapeutics
Pharmacology
2018English

Cost-Effectiveness of First-Line Versus Delayed Use of Combination Dapagliflozin and Metformin in Patients With Type 2 Diabetes

Scientific Reports
Multidisciplinary
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy